Cytosorbents Corporation (CTSO)
Cytosorbents Corporation focuses on blood purification technology. Their flagship product, CytoSorb, addresses critical care applications like sepsis and organ transplantation.
Company Overview
Cytosorbents Corporation pioneers blood purification with its CytoSorb technology, targeting critical care applications and organ transplantation. With a strong gross margin of 78.7%, CTSO offers investors a unique opportunity in the medical device sector, driven by innovative solutions and expanding clinical applications.
Investment Thesis
Cytosorbents Corporation presents a compelling investment opportunity within the medical device sector. The company's CytoSorb technology addresses critical unmet needs in sepsis treatment, organ transplantation, and other critical care applications. With a high gross margin of 78.7%, Cytosorbents demonstrates the potential for profitability as it scales its operations. Key growth catalysts include expanding regulatory approvals for CytoSorb in new geographies and clinical applications, as well as the development and commercialization of its pipeline products like VetResQ and HemoDefend. The company's focus on innovative blood purification solutions positions it favorably in a growing market, making it an attractive investment for those seeking exposure to the healthcare sector. The current market capitalization of $0.04 billion offers significant upside potential as the company executes its growth strategy.
Key Highlights
- CytoSorb is the flagship product, an extracorporeal cytokine filter for adjunctive therapy.
- Gross margin of 78.7% indicates strong potential for profitability.
- Developing VetResQ for veterinary applications, expanding market reach.
- HemoDefend blood purification technology platform to reduce contaminants in the blood supply.
- Market Cap of $0.04B indicates significant growth potential.
Competitors
Strengths
- Proprietary CytoSorb technology with proven efficacy.
- High gross margin of 78.7%.
- Expanding product pipeline with VetResQ and HemoDefend.
- Established presence in critical care settings.
Weaknesses
- Negative profit margin of -28.6%.
- Reliance on CytoSorb for a significant portion of revenue.
- Limited market capitalization of $0.04B.
- Dependence on regulatory approvals for new products and indications.
Catalysts
- Ongoing: Expansion of CytoSorb's approved indications to include ARDS and severe burns.
- Ongoing: Geographic expansion into new markets in Asia and Latin America.
- Upcoming: Clinical trial results for VetResQ in veterinary applications.
- Upcoming: Regulatory approvals for HemoDefend for blood supply purification.
- Ongoing: Increased adoption of CytoSorb in existing markets through education and marketing efforts.
Risks
- Potential: Competition from established medical device companies with greater resources.
- Ongoing: Regulatory hurdles and delays in obtaining approvals for new products and indications.
- Potential: Product liability claims related to the use of CytoSorb.
- Ongoing: Economic downturns affecting hospital budgets and capital expenditures.
- Potential: Dependence on key suppliers for critical components of CytoSorb.
Growth Opportunities
- Expansion of CytoSorb's approved indications: Cytosorbents has the opportunity to expand the approved indications for CytoSorb beyond sepsis to include other critical care applications such as acute respiratory distress syndrome (ARDS) and severe burns. These new indications could significantly increase the addressable market for CytoSorb, driving revenue growth. The timeline for securing these approvals is dependent on clinical trial outcomes and regulatory review processes.
- Geographic expansion into new markets: Cytosorbents can pursue geographic expansion into new markets, particularly in Asia and Latin America, where there is a growing demand for advanced medical technologies. Entering these markets would require regulatory approvals and the establishment of distribution networks, but it could significantly increase the company's revenue base. The timeline for geographic expansion will depend on the specific market and regulatory landscape.
- Development and commercialization of pipeline products: Cytosorbents is developing a pipeline of new products, including VetResQ for veterinary applications and HemoDefend for blood supply purification. Successfully developing and commercializing these products would diversify the company's revenue streams and reduce its reliance on CytoSorb. The timeline for these products to reach the market will depend on the progress of clinical trials and regulatory approvals.
- Strategic partnerships and acquisitions: Cytosorbents could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. These partnerships could provide access to new markets, technologies, or distribution channels, accelerating the company's growth. The timeline for these partnerships will depend on the availability of suitable targets and the negotiation process.
- Increased adoption of CytoSorb in existing markets: Cytosorbents can focus on increasing the adoption of CytoSorb in its existing markets by educating healthcare providers about the benefits of the technology and expanding its sales and marketing efforts. This would involve conducting clinical studies to demonstrate the efficacy of CytoSorb and building relationships with key opinion leaders. The timeline for increased adoption will depend on the effectiveness of these efforts.
Opportunities
- Expansion into new geographic markets.
- Increased adoption of CytoSorb in existing markets.
- Development of new applications for CytoSorb technology.
- Strategic partnerships and acquisitions.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and delays in approvals.
- Potential for product liability claims.
- Economic downturns affecting hospital budgets.
Competitive Advantages
- Proprietary adsorbent and porous polymer technology.
- Established brand recognition for CytoSorb in critical care.
- Growing portfolio of blood purification products.
- Strong relationships with key opinion leaders in the medical community.
About
Founded in 1997 and headquartered in Princeton, New Jersey, Cytosorbents Corporation is a medical device company specializing in blood purification technologies. Originally named MedaSorb Technologies Corporation, the company rebranded in 2010 to reflect its focus on innovative sorbent technology. Cytosorbents' core technology platform revolves around a proprietary adsorbent and porous polymer technology used in its flagship product, CytoSorb. CytoSorb is an extracorporeal cytokine filter designed for adjunctive therapy in critical care applications, including the treatment of sepsis, prevention of perioperative complications during cardiopulmonary bypass surgery, and enhancement of the quality of solid organs for transplantation. Beyond CytoSorb, the company is developing a portfolio of products, including VetResQ for veterinary applications, CytoSorb-XL for enhanced sepsis treatment, HemoDefend for blood supply purification, K+ontrol for hyperkalemia, and ContrastSorb for contrast-induced nephropathy. Cytosorbents is also exploring BetaSorb for renal failure complications, DrugSorb for removing toxic chemicals, and DrugSorb-ATR for antithrombotic removal, showcasing its commitment to expanding the applications of its core technology.
What They Do
- Develops and commercializes blood purification medical devices.
- Offers CytoSorb, an extracorporeal cytokine filter for critical care.
- Targets sepsis treatment and prevention of complications during surgery.
- Enhances the quality of solid organs for transplantation.
- Develops VetResQ for veterinary applications.
- Creates HemoDefend for blood supply purification.
- Working on K+ontrol for hyperkalemia treatment.
- Developing ContrastSorb to reduce contrast-induced nephropathy.
Business Model
- Sells CytoSorb and other blood purification devices to hospitals and clinics.
- Generates revenue from direct sales and distribution agreements.
- Focuses on expanding product applications and geographic reach.
- Invests in research and development to create new products and improve existing ones.
Industry Context
Cytosorbents operates within the medical device industry, specifically focusing on blood purification technologies. The market for blood purification devices is driven by the increasing prevalence of sepsis, kidney diseases, and the growing demand for organ transplantation. The competitive landscape includes companies like BDMD, BDSX, ECOR, ICCM, and MDAI, which offer various blood purification and medical device solutions. Cytosorbents differentiates itself through its proprietary CytoSorb technology, which targets cytokine removal in critical care settings. The industry is characterized by stringent regulatory requirements and a focus on innovation to improve patient outcomes.
Key Customers
- Hospitals and intensive care units (ICUs).
- Organ transplant centers.
- Veterinary clinics and hospitals.
- Blood banks and transfusion centers.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9M | -$3M | $-0.05 |
| Q2 2025 | $10M | $2M | $0.03 |
| Q1 2025 | $9M | -$1M | $-0.02 |
| Q4 2024 | $9M | -$8M | $-0.14 |
Source: Company filings
Chart & Info
Price Chart
Cytosorbents Corporation (CTSO) stock price: $0.64 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in the company's future prospects, mirroring situations where management sees undervalued potential.
- •The community sentiment seems generally positive, with many expressing optimism about the company's technology and its potential applications.
- •There's a growing perception that the company's addressing a critical need in healthcare, which could drive future demand for its products. Think of the early days of companies solving urgent problems.
- •The company's market perception seems to be improving, with more analysts and investors recognizing its unique value proposition.
Why Bear
- •Some insiders have sold shares recently, which could signal concerns about the company's near-term performance or market conditions.
- •The community sentiment also reveals some skepticism about the company's ability to scale its operations effectively.
- •There are concerns that the company's market perception is overly optimistic, potentially leading to a correction if expectations aren't met.
- •Recent market developments have created some uncertainty about the company's ability to maintain its growth trajectory, similar to periods of sector-wide downturns.
Latest News
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
-
Earnings Scheduled For August 7, 2025
benzinga · Aug 7, 2025
-
Earnings Scheduled For May 14, 2025
benzinga · May 14, 2025
Technical Analysis
Rationale
AI-generated technical analysis for CTSO including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Cytosorbents Corporation (CTSO) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for CTSO.
Make a Prediction
Set your price target for Cytosorbents Corporation (CTSO), choose a timeframe, and track your prediction accuracy.
Current price: $0.64
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTSO.
Price Targets
Wall Street price target analysis for CTSO.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 7.8% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 10/100
Gross margin of 70.8% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates CTSO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Cytosorbents Corporation do?
Cytosorbents Corporation is a medical device company focused on blood purification technologies. Its primary product, CytoSorb, is an extracorporeal cytokine filter used in critical care settings to treat conditions like sepsis, prevent complications during surgery, and enhance the quality of organs for transplantation. The company develops and commercializes devices that remove harmful substances from the blood, aiming to improve patient outcomes in life-threatening conditions. Additionally, Cytosorbents is expanding its portfolio with products like VetResQ for veterinary medicine and HemoDefend for blood supply purification, demonstrating its commitment to innovation in blood purification.
Is CTSO stock a good buy?
CTSO stock presents a mixed investment profile. The company's high gross margin of 78.7% suggests strong potential for profitability, but its negative profit margin of -28.6% raises concerns about its current financial performance. The company's innovative CytoSorb technology and expanding product pipeline offer growth opportunities, but regulatory hurdles and competition pose risks. Investors should carefully consider the company's financial performance, growth prospects, and risk factors before making an investment decision. The market capitalization of $0.04 billion indicates significant growth potential if the company can execute its strategy effectively.
What are the main risks for CTSO?
The main risks for Cytosorbents include competition from larger, more established medical device companies, regulatory hurdles and potential delays in obtaining approvals for new products and indications, and the potential for product liability claims related to the use of CytoSorb. Economic downturns could also affect hospital budgets, reducing demand for the company's products. Additionally, Cytosorbents relies on key suppliers for critical components of CytoSorb, and any disruption in the supply chain could negatively impact its operations. These factors could impact the company's ability to achieve its growth targets and maintain profitability.
Is CTSO a good stock to buy?
Whether CTSO is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the CTSO MoonshotScore?
The MoonshotScore for CTSO is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is CTSO data updated?
CTSO stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CTSO is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for CTSO?
Growth catalysts for Cytosorbents Corporation (CTSO) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Cytosorbents Corporation's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are CTSO's main competitors?
Cytosorbents Corporation (CTSO) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CTSO has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about CTSO?
Wall Street analyst coverage for CTSO includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is CTSO's market cap?
Market capitalization (market cap) for CTSO is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CTSO's current market cap alongside enterprise value and other valuation metrics.
How has CTSO stock performed recently?
CTSO's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CTSO's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in CTSO?
Key risk categories for CTSO include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CTSO's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling CTSO?
Insider trading activity for CTSO tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is CTSO a good stock for beginners?
Cytosorbents Corporation (CTSO) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is CTSO for first-time investors?
Every stock carries risk, including Cytosorbents Corporation (CTSO). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CTSO.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Future performance is subject to market conditions and company-specific factors.